UK mi­cro­cap faces par­tial clin­i­cal hold in mid-stage IPF tri­al

A tiny UK biotech is work­ing on re­solv­ing a par­tial clin­i­cal hold from the FDA on some co­horts of its mid-stage tri­al, with the com­pa­ny say­ing the de­lay is un­re­lat­ed to clin­i­cal da­ta.

Redx Phar­ma said Thurs­day that US en­roll­ment in­to 12-week co­horts of a Phase IIa study has not been able to get start­ed, al­though there is an open IND in the US. CEO Lisa An­son — re­cruit­ed in 2018 from As­traZeneca, where she served as the Big Phar­ma’s UK pres­i­dent for six years — told End­points News that the FDA is ask­ing for spe­cif­ic da­ta from a study in dogs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.